Welcome to our dedicated page for TCDA news (Ticker: TCDA), a resource for investors and traders seeking the latest updates and insights on TCDA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TCDA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TCDA's position in the market.
Tricida, Inc. (Nasdaq: TCDA) announced its Q3 2021 financial results, reporting a net loss of $39.7 million compared to $77.7 million in Q3 2020. R&D expenses decreased to $26.6 million from $43 million year-over-year. The VALOR-CKD clinical trial has randomized over 1,470 subjects, but Tricida anticipates an early termination due to resource constraints, aiming for completion by mid-2022. Cash and investments stood at $146.8 million as of September 30, 2021, providing runway through 2022 amidst ongoing challenges in the clinical trial.
Tricida, Inc. (Nasdaq: TCDA) will release its third quarter 2021 financial results on November 8, 2021, after market close. The conference call and webcast will take place at 4:30 PM ET. Interested parties can access the presentation through their website or via dial-in numbers provided. Tricida focuses on developing veverimer, an investigational drug candidate aimed at slowing the progression of chronic kidney disease (CKD) in patients suffering from metabolic acidosis. The VALOR-CKD trial is currently assessing veverimer's efficacy against CKD progression.
Tricida, Inc. (Nasdaq: TCDA) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will provide an overview and update on the company's key initiatives and will be available on their website at 4:00 am PT / 7:00 am ET. An archived version will be accessible for 90 days. Tricida focuses on the development of veverimer, a drug candidate aimed at slowing chronic kidney disease progression in patients with metabolic acidosis, a condition affecting around three million CKD patients in the U.S.
Tricida, a pharmaceutical company focused on veverimer for chronic kidney disease (CKD), reported its Q2 2021 financial results. The VALOR-CKD trial has randomized 1,455 out of 1,600 subjects, with an interim analysis planned for mid-2022. Financially, R&D expenses decreased to $19.8 million, down from $28.8 million, and net loss reduced to $33.6 million compared to $58.2 million in the previous year. As of June 30, 2021, cash reserves were $175.8 million, expected to last into late 2022, supporting ongoing operations.
Tricida, Inc. (TCDA) will report its Q2 2021 financial results on August 9, 2021. Following the release, a conference call and webcast will be held at 4:30 pm ET to discuss the results and business progress. The company focuses on developing veverimer, which addresses chronic metabolic acidosis in CKD patients, impacting an estimated three million individuals in the U.S. This condition currently lacks FDA-approved treatments.
Investors can access the call via dial-in or through their website.
Tricida, Inc. (Nasdaq: TCDA) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 12:50 pm PT. CEO Gerrit Klaerner will discuss the company's initiatives and recent developments.
A live webcast of the event will be available on the Tricida website, with an archive accessible post-event. The company is focused on developing veverimer, a novel treatment for metabolic acidosis linked to chronic kidney disease. This condition affects around three million CKD patients in the U.S., with no existing FDA-approved therapies.
Tricida, Inc. (Nasdaq: TCDA) reported its financial results for Q1 2021, with a net loss of $53.4 million, down from $74.1 million in Q1 2020. The company continues its VALOR-CKD renal outcomes trial, having randomized 1,440 out of 1,600 subjects as of May 4, 2021. Research and development expenses decreased to $32.2 million, while general and administrative expenses also fell to $9.9 million. Tricida anticipates having sufficient financial resources to support operations into late 2022 and expects interim analyses of the trial in 2021 and 2022.
Tricida, Inc. (Nasdaq: TCDA) will report its Q1 2021 financial results on May 6, 2021, at 4:30 PM ET. Following the results, a conference call and webcast will provide insights into the company's progress. Tricida focuses on developing the oral drug veverimer to treat metabolic acidosis in chronic kidney disease (CKD) patients, a condition affecting an estimated three million individuals in the U.S. The company emphasizes its commitment to addressing significant health risks associated with CKD.
Tricida, Inc. (Nasdaq: TCDA) announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 12:45 pm PT. The company will present a business update and its key initiatives. A live webcast will be available on the Tricida website, with an archived version accessible for 90 days post-presentation. Tricida focuses on developing veverimer, an investigational drug aimed at treating metabolic acidosis in chronic kidney disease (CKD) patients. This condition affects around three million CKD patients in the U.S.
FAQ
What is the market cap of TCDA (TCDA)?
